Skip to main content
. Author manuscript; available in PMC: 2024 Oct 27.
Published in final edited form as: Neurobiol Dis. 2024 Aug 24;200:106647. doi: 10.1016/j.nbd.2024.106647

Fig. 3.

Fig. 3.

Phenotype validation experiments, part 2 (6 months post-injection; 8 weeks of age): Motor impairment (En1/PBS in yellow, En1/SYN in red, WT/PBS in blue, WT/SYN in green). One-way ANOVA, ANCOVA, multiple comparisons test with Bonferroni correction (see data availability for additional comparisons). A) CatWalk Gait impairment: 1 mouse/marker, En1/PBS n = 16, En1/SYN n = 12, WT/PBS n = 19, WT/SYN n = 22. Significant effect of treatment between En1/SYN and WT/PBS on total runs to acquire compliant-run 2 (p = 0.002, En1/SYN vs WT/PBS p = 0.043), total runs to acquire compliant-run 6 (p < 0.001, En1/SYN vs WT/PBS p < 0.001), forepaw stride length (p = 0.012, En1/SYN vs WT/PBS p = 0.045), and left forepaw to right hindpaw coupling (p = 0.006, En1/SYN vs WT/PBS p = 0.042). B) Open field total distance (m): 1 mouse/marker, bars = treatment group means, error bars (±SEM). Significant effect of treatment (p = 0.0003, En1/SYN vs WT/PBS p = 0.001). C) Rotarod RPMs to fall: En1/PBS n = 16, En1/SYN n = 11, WT/PBS n = 20, WT/SYN n = 21. Significant effect of treatment (p = 0.013, En1/SYN vs WT/PBS p = 0.0116).